Table 1.
PICOS eligibility criteria for study inclusion.
Fig 1.
PRISMA diagram of the selection process of the included publications.
Note: † Studies reporting evidence of statistically significant prognostic indicator of disease progression in DMD. Systematic literature reviews (SLRs). Meta-analyses (MAs).
Table 2.
Characteristics of included studies and identified prognostic indicators in DMD.
Fig 2.
Evidence of prognostic indicators of disease progression in DMD.
Note: Numbers shown in the coloured squares refer to the number of studies reporting of the specific indicator. † Angiotensin-converting enzyme (ACE) inhibitors, beta blockers, and/or diuretics. ‡ Age at treatment initiation, dose, duration of exposure, pharmacological agent, and regimen. Duchenne muscular dystrophy (DMD).